Augere Medical

Executive Summary

Augere Medical is a Norwegian medtech company developing PolypAID™, an AI-powered colonoscopy guidance platform aimed at improving polyp detection rates during colorectal cancer screening. The platform provides real-time visual assistance to endoscopists, with a focus on transparent AI that highlights suspicious areas without disrupting workflow. Founded in 2018 and based in Oslo, the company addresses a critical unmet need: colorectal cancer is the third most common cancer worldwide, and adenoma detection rates are highly operator-dependent. PolypAID™ has the potential to reduce missed polyps, thereby improving patient outcomes and reducing healthcare costs. Augere Medical is currently in the commercialization phase, targeting European markets with a CE mark application underway. The company differentiates itself by offering a software-only solution that integrates with existing endoscopy systems, minimizing adoption barriers. Early clinical studies have shown promising sensitivity and specificity, but larger validation trials are ongoing. With the global AI in endoscopy market projected to grow rapidly, Augere Medical is well-positioned to capture a share, though it faces competition from established players. The company's success hinges on regulatory approvals, clinical evidence, and commercial partnerships.

Upcoming Catalysts (preview)

• H2 2026CE Mark Approval for PolypAID™75% success
• Q1 2027Publication of Pivotal Clinical Study Results70% success
• H1 2027Strategic Partnership with Major Endoscopy Distributor60% success